Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1086 in advanced solid tumors
NCT07118709Phase 1Not yet recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of KC1086 in solid tumor, sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoint: Adverse Events at 3 years. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
KC1086
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07118709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118709.